Bank Of America Corp Aveo Pharmaceuticals, Inc. Transaction History

Bank Of America Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$8.48 - $14.97 $276,744 - $488,545	-32,635 Reduced 59.89%	21,854 $326,000
Q3 2022 Nov 14, 2022	BUY	$6.61 - $8.72 $36,599 - $48,282	5,537 Added 11.31%	54,489 $449,000
Q2 2022 Aug 12, 2022	SELL	$3.51 - $6.67 $266 - $506	-76 Reduced 0.16%	48,952 $321,000
Q1 2022 May 16, 2022	SELL	$3.15 - $6.01 $54,907 - $104,760	-17,431 Reduced 26.23%	49,028 $274,000
Q4 2021 Feb 08, 2022	SELL	$4.69 - $7.4 $122,868 - $193,865	-26,198 Reduced 28.27%	66,459 $311,000
Q3 2021 Nov 15, 2021	BUY	$5.12 - $6.89 $321,356 - $432,450	62,765 Added 209.97%	92,657 $573,000
Q2 2021 Sep 13, 2021	BUY	$6.21 - $7.45 $185,629 - $222,695	29,892 New	29,892 $197,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.